newsfilter
← Earnings
Earnings Releases·

Vanda Pharmaceuticals — Third Quarter 2026 Earnings Summary

Vanda Pharmaceuticals reported third-quarter 2026 total revenues of $69.8 million, representing a 24% increase year-over-year driven by Fanapt and early NEREUS sales. Total operating expenses decreased 18% to $93.3 million in the quarter as key Phase III and launch-preparation activities concluded. The company announced positive Phase III results for NEREUS in preventing GLP-1-induced vomiting and confirmed that the Quimilza BLA for generalized pustular psoriasis is under FDA review with a PDUFA date of December 12, 2026. Additionally, the commercial launch of BYSANTI is expected in the fourth quarter of 2026, and the company updated its full-year 2026 revenue guidance to exceed $240 million.

Company
VANDA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology